Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2014; 20(48): 18413-18419
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18413
Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer
Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng
Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China
Author contributions: Yu YJ prepared the manuscript and supervised the research; Sun WJ collected the patients’ data; Lu MD made sample grouping and delivery; Wang FH performed preoperative data analysis and operation; Qi DS performed the pathological examination; Zhang Y contributed to the collection and comparison of influencing factors; Li PH performed the iconographical examination; Huang H made statistics of the patients’ data; You T performed the operation and sample grouping; and Zheng ZQ performed the operation and guided the research.
Correspondence to: Yao-Jun Yu, MD, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, No. 109, Xueyuan Road, Wenzhou 325003, Zhejiang Province, China. yuyaojun26@163.com
Telephone: +86-577-88002709 Fax: +86-577-88002739
Received: March 8, 2014
Revised: September 15, 2014
Accepted: October 21, 2014
Published online: December 28, 2014
Processing time: 303 Days and 23 Hours
Abstract

AIM: To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer.

METHODS: A total of 53 stage III/IV gastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy. Two of the cases were excluded. The program was as follows: 75 mg/m2 docetaxel and 85 mg/m2 oxaliplatin on day 1 and 1500 mg/m2 fluorouracil on days 1 to 3 for three weeks.

RESULTS: The tumour changes, postoperative remission rate, changes in the symptoms and adverse reactions were observed. The overall clinical efficacy (complete remission + partial remission) of the neoadjuvant chemotherapy was 62.7%. R0 radical resection was performed on 60.8% of the patients, with a remission rate (pathological complete response + pathological subtotal response + pathological partial response) of 74.2%. The Karnofksy score improved in 42 cases. The toxicity reactions mostly included myelosuppression, followed by gastrointestinal mucosal lesions, nausea, vomiting and diarrhoea.

CONCLUSION: Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III/IV gastric cancer. However, the treatment is associated with a high incidence of bone marrow suppression, which should be managed clinically.

Keywords: Gastric cancer; Neoadjuvant chemotherapy; Docetaxel; Oxaliplatin

Core tip: This study analysed the combination of docetaxel, oxaliplatin and fluorouracil in the neoadjuvant chemotherapy towards stage III/IV gastric cancer patients, and observed the changes of tumours after chemotherapy, as well as the surgical resection rate, postoperative pathological remission degree, clinical symptom remission degree and adverse reactions, aiming to verify the effectiveness and safety of this regimen in clinical applications.